Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy

B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy of B-type lymphoid precursor cells. Minimal/measurable residual disease (MRD) is an important prognostic factor for B-ALL relapse. Traditional flow cytometry detection mainly relies on CD19-based gating strategies. However, rela...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of hematology Vol. 113; no. 3; pp. 337 - 343
Main Authors Liu, Zhiyu, Li, Yang, Shi, Ce
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.03.2021
Springer Nature B.V
Subjects
Acute lymphoblastic leukemia
CD19 antigen
Flow cytometry
Gating
Hematology
Leukemia
Lymphatic leukemia
Lymphocytes B
Malignancy
Medicine
Medicine & Public Health
Oncology
Review Article
Acute lymphoblastic leukemia
Targeted therapy
Minimal/measurable residual disease
Online AccessGet full text

Cover

More Information
Summary:B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic malignancy of B-type lymphoid precursor cells. Minimal/measurable residual disease (MRD) is an important prognostic factor for B-ALL relapse. Traditional flow cytometry detection mainly relies on CD19-based gating strategies. However, relapse of CD19-negative B-ALL frequently occurs in patients who receive cellular and targeted therapy. This review will summarize the technical aspects of standard MRD assessment in B-ALL by flow cytometry, and then discuss the challenges of MRD strategies to deal with the scenario of CD19 negative or dim B-ALL relapse.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-021-03085-y